Hanrahan, J.P.; Wakefield, J.D.; Wilson, P.J.; Miller, P; Chickering, J; Morrow, L; Hall, M.L.; Currie, M; Milne, G.T.; Profy, A.T.
Presentation at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL, June 2018.
About this Poster:
Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, has been shown to augment nitric oxide (NO) signaling and reduce fasting plasma glucose and proteinuria in an animal model of diabetic nephropathy. In healthy adults, repeated oral doses of 15-40 mg were tolerated and lowered blood pressure (BP).